Amgen (AMGN) Reports Q4 Earnings: What Key Metrics Have to Say

Amgen (AMGN) reported $8.2 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 19.8%. EPS of $4.71 for the same period compares to $4.09 a year ago.

The reported revenue represents a surprise of +1.00% over the Zacks Consensus Estimate of $8.11 billion. With the consensus EPS estimate being $4.66, the EPS surprise was +1.07%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Amgen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Sales- EPOGEN - US: $55 million versus $52.80 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -51.8% change.
• Product Sales- ENBREL - US: $1.01 billion compared to the $1.04 billion average estimate based on six analysts. The reported number represents a change of -6.9% year over year.
• Product Sales- Aranesp - ROW: $212 million versus the six-analyst average estimate of $214.69 million. The reported number represents a year-over-year change of -5.4%.
• Product Sales- Aranesp - US: $107 million compared to the $114.21 million average estimate based on six analysts. The reported number represents a change of -13.7% year over year.
• Revenue- Product sales: $7.83 billion versus $7.77 billion estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +19.6% change.
• Revenue- Other revenues: $363 million versus $344.69 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +26.5% change.
• Product Sales- Aimovig - Total: $78 million versus the nine-analyst average estimate of $98.11 million. The reported number represents a year-over-year change of -31.6%.
• Product Sales- Aranesp - Total: $319 million versus $332.42 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -8.3% change.
• Product Sales- BLINCYTO - Total: $241 million versus the nine-analyst average estimate of $227.25 million. The reported number represents a year-over-year change of +47%.
• Product Sales- Repatha - Total: $417 million compared to the $428.04 million average estimate based on nine analysts. The reported number represents a change of +25.2% year over year.
• Product Sales- EPOGEN -Total: $55 million versus $52.80 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -51.8% change.
• Product Sales- Neulasta - Total: $239 million versus the nine-analyst average estimate of $152.94 million. The reported number represents a year-over-year change of +8.1%.

*7 Best Stocks for the Next 30 Days

*Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

*Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research